Skip to content

Plasma proteomic profiling in patients with atopic dermatitis following the administration of Nemolizumab

Plasma proteomic profiling in patients with atopic dermatitis following the administration of Nemolizumab

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-jRCT1030230474
Enrollment
35
Registered
2023-11-22
Start date
2023-11-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

None listed

Sponsors

Uratsuji Hideya
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Group with AD patients Stored plasma samples collected from AD patients with moderate or severe pruritus in the clinical trial (jRCT2080225290) will be used. 2)Group with healthy volunteers Individuals who have never been diagnosed with AD in the past and are not currently diagnosed with AD Individuals who can collect blood samples following a set procedure

Exclusion criteria

Exclusion criteria: Group with healthy volunteers Individuals with a history of, or currently suffering from, severe diseases, including severe allergic diseases Individuals who have administered medications containing immunomodulatory drugs (immunosuppressants, steroids or biological agents) within one month for topical drugs and within six months for oral or injectable drugs, counting from the blood collection date Individuals who are currently undergoing treatment for a disease or who have received treatment within the past week Individuals with a constitution such as atopic predisposition or allergy-prone Individuals who have been advised to seek treatment or more serious intervention based on their most recent regular health check-up Individuals who fall under the conditions listed in the 'Cases where you should refrain from donating' section on the Japanese Red Cross Society website Individuals with a history of, or currently suffering from, drug or alcohol dependency Individuals who are pregnant or currently breastfeeding Individuals considered inappropriate for the study by the principal investigator of the clinical research

Design outcomes

Primary

MeasureTime frame
This study will perform explorative analysis of the temporal variations of each factor, using the pre-administration measurements of healthy adults and AD patients as controls. Based on these temporal variations, we will cluster the AD patients and perform pathway analysis for each cluster.

Contacts

Public ContactHideya Uratsuji

Maruho Co.,Ltd.

uratsuji_cpv@mii.maruho.co.jp+81-6-6371-8913

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026